Psoriatic Arthritis Market

DelveInsight’s ‘Psoriatic Arthritis (PsA)– Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Psoriatic Arthritis in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Psoriatic Arthritis market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Psoriatic Arthritis Market Size from 2018 to 2030, segmented by 7MM major markets. The report also covers the current Psoriatic Arthritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2018–2030

Psoriatic Arthritis: Disease Understanding and Treatment Algorithm

Psoriatic Arthritis Overview

Psoriatic Arthritis (PsA) is a form of arthritis associated with psoriasis, chronic skin, and nail disease characterized by red, scaly rashes, and thick pitted fingernails. The disease is similar to rheumatoid arthritis in symptoms, characterized by joint inflammation. However, Psoriatic Arthritis tends to affect fewer joints than rheumatoid arthritis and does not produce the typical rheumatoid arthritis antibodies.

Arthritis associated with psoriasis was first described in 1956 by Wright. However, it was not until 1973 that Moll and Wright defined the various clinical phenotypes, including axial PsA, symmetrical polyarthritis, asymmetrical oligoarthritis, distal interphalangeal (DIP) arthritis, and arthritis mutilans. The following year, these authors introduced the concept of spondyloarthritis, a cluster of diseases with shared clinical and immunogenetic features. Despite these advances, the immunopathogenesis of PsA remained poorly understood, awaiting a more detailed understanding of immune networks and the inflammatory response.

The etiology and pathogenesis of PsA involve a complex interaction between genetic and environmental factors resulting in immune-mediated inflammation involving the skin and joints and may involve other organs. Approximately 33–50% of Psoriatic Arthritis patients have at least one first-degree relative who also has psoriasis or PsA. Genes associated with PsA include those in the HLA region, which are involved in antigen presentation and immune recognition along withnon-HLA genes involved in immune activation and inflammation including intracellular signaling, cytokine expression, and signaling, and T-cell effector function. The role of environmental factors is suspected but has been difficult to confirm. Skin trauma is known to induce flares of psoriatic skin lesions known as the Koebner phenomenon. There is evidence the joint trauma may induce a flare of arthritis, referred to as the “internal” or “deep” Koebner phenomenon.

PsA shares some clinical features with other inflammatory arthritides, including rheumatoid arthritis (RA), reactive arthritis (ReA), and ankylosing spondylitis (AS). In some cases, it is difficult to make a precise diagnose. Unlike PsA, RA tends to be symmetrical and generally spares the DIP joints. AS has an earlier age of onset compared to Psoriatic Arthritis, and sacroiliac involvement is usually symmetric rather than asymmetric.

There are no laboratory tests that are specific for PsA. Acute phase reactants such as ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein) may become elevated as in most inflammatory diseases. However, a normal ESR and CRP should not be used to rule out a diagnosis of PsA as these levels increase in only about 40% of patients. Besides, imaging plays a central role. Classical radiography has been used for this purpose for over a hundred years. It allows identifying the late stages of the disease when bone tissue is affected. In the last 20 years, many new imaging modalities, such as ultrasonography (US), computed tomography (CT), and magnetic resonance (MR), have been developed and became important diagnostic tools for the evaluation of rheumatoid diseases. They enable the assessment and monitoring of early inflammatory changes. As a result, patients have earlier access to modern treatment, and thus the formation of destructive changes in joints can be markedly delayed or even avoided.

PsA may range from mild to severe, and it is crucial to treat it no matter the severity. If left untreated, PsA can cause permanent joint damage, which may be disabling. In addition to preventing irreversible joint damage, treating PsA may also help reduce inflammation in the body, leading to other diseases. These other diseases are often referred to as comorbidities. However, at present, no cure for PsA exists, so treatment goals are to slow disease progression, improve quality of life, lessen pain, and preserve the range of motion. In most patients with PsA, pharmacological treatment consists of a trial-and-error approach, beginning with corticosteroids and nonsteroidal anti-inflammatory drugs to manage symptoms. Physicians often use conventional synthetic disease-modifying antirheumatic drugs (DMARDs), followed by biological DMARDs if a patient does not adequately respond.

Psoriatic Arthritis Diagnosis and Treatment

It covers conventional and current medical therapies and diagnosis available in the Psoriatic Arthritis market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Psoriatic Arthritis market report thoroughly understands Psoriatic Arthritis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for Psoriatic Arthritis in the US, Europe, and Japan.

Psoriatic Arthritis Epidemiology

The Psoriatic Arthritis epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Psoriatic Arthritis epidemiology segmented as the Prevalent Cases of Psoriatic Arthritis, diagnosed cases of Psoriatic Arthritis, Age-specific Cases of Psoriatic Arthritis, Gender-specific cases of Psoriatic Arthritis, and Severity-specific Prevalence of Psoriatic Arthritis. The report includes the prevalent scenario of Psoriatic Arthritis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Psoriatic Arthritis Epidemiology

The epidemiology segment also provides the Psoriatic Arthritis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total diagnosed prevalence population of Psoriatic Arthritis in the 7MM was estimated to be 1,486,869 cases in 2020.

Psoriatic Arthritis Drug Chapters

The drug chapter segment of the Psoriatic Arthritis report encloses the detailed analysis of Psoriatic Arthritis marketed drugs and late stage (Phase-III, Phase-II and Phase-I/II) pipeline drugs. It also helps to understand the Psoriatic Arthritis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

PsA treatments are not one-size-fits-all; the current treatment strategy in PsA emphasizes a target to target approach to the prevalent domains. Advances in the knowledge of pathogenesis have led to the development of novel biologics beyond anti-TNFs. However, there is still a substantial proportion of patients who may not respond to certain treatment options. The current practice relies on individualizing treatment choice by matching the most severely affected domains of the patients with the best available evidence of efficacies of drugs for those domains. When patients do not respond to treatment, shifting and cycling through different options would be rational.

Products detail in the report…

Psoriatic Arthritis Emerging Drugs

Skyrizi (AbbVie) is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is linked to several chronic immune-mediated diseases, including psoriasis. Skyrizi received US Food and Drug Administration (FDA) approval to treat moderate-to-severe plaque psoriasis (Ps) in adults who are candidates for systemic therapy or phototherapy. The drug is approved in Japan for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis, and PsA in adults who have an inadequate response to conventional therapies. Phase III trials of Skyrizi in psoriasis, Crohn’s disease, and PsA are ongoing. With positive top-line results from two important phases III trials for Psoriatic Arthritis, the company filed regulatory submissions for PsA in FDA and EMA and expects FDA approval for treating Psoriatic Arthritis in 2022.

Ilumya (tildrakizumab-asmn) (Sun Pharma) is an interleukin-23 (IL-23) inhibitor, already indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, in the United States, Australia, and Japan and under the brand name ILUMETRI in Europe. The drug is currently under phase III evaluation and is expected to enter the market by 2023.

Products detail in the report…

Psoriatic Arthritis Market Outlook

The Psoriatic Arthritis market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Psoriatic Arthritis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Psoriatic Arthritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to clearly view the market at first sight.

According to DelveInsight, the Psoriatic Arthritis market in the 7MM is expected to change in the study period 2018–2030.

Rising awareness about the disease, evolving patient research prospective, supporting government policies, funds, approvals, and emerging research would significantly drive the market in the forecast period (2021–2030).

AbbVie holds the highest market position among all the current pharma players despite facing tough competition and the emergence of biosimilars due to its strategic launch of two candidate drugs Rinvoq and Skyrizi, in the upcoming years. Both the drugs are already approved in the US and EU market: Rinvoq to treat moderately to severely active rheumatoid arthritis and risankizumab to treat moderate to severe plaque psoriasis. Also, Rinvoq got the latest approval in the EU market for PsA, and Skyrizi is already approved in Japan. Hence, with the subsequent launch of these drugs, Abbvie is likely to continue to dominate the therapeutic market.

Key Findings

This section includes a glimpse of the Psoriatic Arthritis market in the 7MM. The market size of Psoriatic Arthritis in the 7MM was USD 6420 Million in 2020.

The United States: Market Outlook

This section provides the total Psoriatic Arthritis market size and market size by therapies of Psoriatic Arthritis in the United States.

The United States accounts for the highest market size of Psoriatic Arthritis compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Ever since the Food and Drug Administration (FDA) granted Enbrel (etanercept) marketing authorization for the treatment of PsA in 2002, the market has become increasingly competitive as more biologics for PsA come to market. Also, with the emergence of numerous treatment options, the treatment guidelines have been further updated to reflect the improved efficacy and safety of these newer medications on the market.

The American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF) recently issued evidence-based guidelines for the pharmacologic and nonpharmacologic treatment of active Psoriatic Arthritis. The number of disease-modifying antirheumatic drugs (DMARDs) indicated for PsA has increased during the last decade. The armamentarium now includes not only conventional synthetic DMARDs (csDMARDs) such as methotrexate (MTX), sulfasalazine and leflunomide, and tumor necrosis factor inhibitors (TNFi), but also other targeted biological agents aimed at different cytokines, such as TNF, interleukin (IL)-12/23 and IL-17A, as well as targeted synthetic DMARDs (tsDMARDs) that inhibit phosphodiesterase-4 (PDE4) or Janus kinases (JAKs).

EU-5 Countries: Market Outlook

The total Psoriatic Arthritis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.

Japan Market Outlook

The total Psoriatic Arthritis market size and market size by therapies of Psoriatic Arthritis in Japan are also mentioned.

Psoriatic Arthritis Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Psoriatic Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Psoriatic Arthritis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase I/II stage. It also analyses Psoriatic Arthritis key players involved in developing targeted therapeutics.

Major players include UCB Biopharma, AbbVie, Bristol-Myers Squibb, Sun Pharma, and others, whose key products are expected to launch in the US market by 20XX.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Psoriatic Arthritis emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in the Psoriatic Arthritis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Psoriatic Arthritis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Psoriatic Arthritis market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Psoriatic Arthritis, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
• Comprehensive insight has been provided into the Psoriatic Arthritis epidemiology and treatment in the 7MM.
• Additionally, an all-inclusive account of both the current and emerging therapies for Psoriatic Arthritis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Psoriatic Arthritis market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies by understanding trends shaping and driving the global Psoriatic Arthritis market.

Report Highlights

• In the coming years, the Psoriatic Arthritis market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world, expanding the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Psoriatic Arthritis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Psoriatic Arthritis. The launch of emerging therapies will significantly impact the Psoriatic Arthritis market
• A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for Psoriatic Arthritis.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Psoriatic Arthritis Report Insights

• Patient Population
• Therapeutic Approaches
• Psoriatic Arthritis Pipeline Analysis
• Psoriatic Arthritis Market Size and Trends
• Market Opportunities
• Impact of Upcoming Therapies

Psoriatic Arthritis Report Key Strengths

• 10-years Forecast
• 7MM Coverage
• Psoriatic Arthritis Epidemiology Segmentation
• Key Competitors
• Highly Analyzed Market
• Drugs Uptake

Psoriatic Arthritis Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What were the Psoriatic Arthritis Market share (%) distribution in 2018, and how would it look like in 2030?
• What would be the Psoriatic Arthritis total market Size and market Size by therapies across the 7MM during the forecast period (2018–2030)?
• What are the key findings pertaining to the market across 7MM, and which country will have the largest Psoriatic Arthritis market Size during the forecast period (2018–2030)?
• At what CAGR, the Psoriatic Arthritis market is expected to grow in the 7MM during the forecast period (2018–2030)?
• What would be the Psoriatic Arthritis market outlook across the 7MM during the forecast period (2018–2030)?
• What would be the Psoriatic Arthritis market growth till 2030, and what will be the resultant market Size in the year 2030?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and unmet needs of Psoriatic Arthritis?
• What is the historical Psoriatic Arthritis patient pool in 7MM major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Psoriatic Arthritis in 7MM major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Psoriatic Arthritis?
• Out of all 7MM countries, which country would have the highest prevalent population of Psoriatic Arthritis during the forecast period (2018–2030)?
• At what CAGR the population is expected to grow in the 7MM during the forecast period (2018–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Psoriatic Arthritis?
• What are the current treatment guidelines for treating Psoriatic Arthritis in the US, Europe, and Japan?
• What are the Psoriatic Arthritis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of Psoriatic Arthritis?
• How many therapies are developed by each company for the treatment of Psoriatic Arthritis?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of Psoriatic Arthritis?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Psoriatic Arthritis therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Psoriatic Arthritis and their status?
• What are the key designations that have been granted for the emerging therapies for Psoriatic Arthritis?
• What are the global historical and forecasted market for Psoriatic Arthritis?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Psoriatic Arthritis market.
• To understand the future market competition in the Psoriatic Arthritis market and an Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Psoriatic Arthritis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Psoriatic Arthritis market.
• To understand the future market competition in the Psoriatic Arthritis market.